Introduction Type 2 cytokines such as IL-13, IL-4 and IL-5 have been shown to play important roles in the pathogenesis of asthma. One source of these cytokines is type 2 CD4 +or CD8+T cells. We have shown that epithelial cells have inhibitory effects on these T cells and that this regulatory effect could be defective in asthma. We have previously shown that type 2 T cell lines release less IL-13 in the presence of epithelial cells and others have shown that epithelial cells are able to reduce division of CD4 +T cells. We wished to extend these studies to determine whether bulk cultures of PBMC were able to release IL-13 and whether this IL-13 was regulated by epithelial cells and whether this was mediated by direct cell contact. Methods We used PBMC from healthy donors and cultured cells in the presence and absence of epithelial cells with titrated doses of IL-2. We used transwells and epithelial cell supernatants to determine whether supernatants were also able to reduce type 2 cytokine secretion. We used size exclusion centrifugation to split supernatants into different fractions. Results After culture of PBMC for 5 days in IL-2, IL-13 release (pg/10 6 cells+/-SD) was 509.95+/-84.95 and was reduced to 37.3+/-7.4 by A549 epithelial cells separated by a transwell. Titration of A549 cells established that inhibition was cell number dependent. Inhibition was not due to scavenging of IL-13 by epithelial cells during co-culture. Less IL-13 was secreted by IL-2 treated PBMC (pg/10 6 cells+/-SD) in the presence of 50% v/v supernatant from healthy HBEC 49 +/-7 or asthma HBEC 90+/-21 p=0.0023. IL-5: HHBEC 14 +/-5 AHBEC 26+/-12 not significant. Splitting the HBEC supernatant into different size fractions showed that the fraction over 3 kD was less inhibitory than the fraction under 3 kD. Conclusion There may be a soluble mediator secreted by epithelial cells that is less than 3 kDa in mass that is able to inhibit type 2 cytokine release from PBMC. These inhibitory factor(s) could contribute to the regulation of type 2 cells that and affect asthma pathogenesis.
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MICRORNAS REGULATE GENOME- Severe asthma represents a significant unmet clinical need and the molecular basis for disease persistence remains inadequately understood. Bronchial epithelial cells, at the interface of environment/tissue, are central to asthma pathogenesis. There is thus a need to evaluate genome-wide changes between health and asthma to better understand the molecular mechanisms underlying disease. The vast majority of genomewide measurements have focused on determining changes at the DNA or mRNA levels, with little attention paid to how and which mRNAs are actually translated into protein. This may not disclose changes happening at the protein level, since mRNA and protein expression correlate poorly. To determine translation and its regulation in bronchial epithelial cells in severe asthma patients we analysed paired genome-wide expression of transcriptional (cytoplasmic) and translational (polyribosome-bound) mRNA levels employing Frac-seq (subcellular fractionation and RNA-sequencing) in primary bronchoepithelium in health and severe asthma patients. We also integrated those data with genome-wide profiling of microRNAs to understand their role in gene expression and impact on the pathophysiology of severe asthma bronchial epithelium. We found both genes (=all isoforms of a gene) and mRNA isoforms differentially expressed in severe asthma airways cells, with dysregulated transcriptional mRNA levels (194 genes) showing little overlap with dysregulated translational mRNA (243 genes) expression. We determined novel inflammatory and remodelling pathophysiological mechanisms disclosed solely by polyribosome-bound mRNAs, centred in epithelium remodelling and repair pathways. We also reveal six dysregulated microRNAs accounting for~90% of all cellular micro-RNA targeting, displaying preferential targeting of~50% of mRNAs undergoing translation in severe asthma airways cells. Thus, microRNAs in human severe asthma are major regulators of translation in airways epithelium and offer potential as future therapeutic targets.
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